Incyte will file for FDA approval of povorcitinib, its oral JAK1 inhibitor pill, in nonsegmental vitiligo after the drug hit in both of its Phase 3 trials.
Both trials met their primary endpoints, giving Incyte the data package needed for an NDA submission.
Povorcitinib blocks the JAK1 enzyme, which drives inflammatory signaling in skin conditions. Vitiligo causes patches of skin to lose their pigmentation, and it’s a condition that has historically been difficult to treat with systemic medicines. The nonsegmental form is the more common and widespread variant of the disease.
The dual win matters commercially. A single Phase 3 success leaves room for questions about reproducibility; two trials clearing gives the NDA a defensible foundation and makes the submission considerably harder to challenge at the FDA review stage.
Incyte hasn’t announced a filing date. Once submitted, the FDA must accept the application before a PDUFA date gets assigned.
Sarah Chen